Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, with adjusted operating expenses at $18.3 million compared to $26.7 million in the prior year [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [29] - The placement program for instruments has successfully secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][11] - The NIH funding environment has shown some improvement, which may positively impact customer capital expenditures [49] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as it prepares for the Proteus launch [4][18] - The Proteus system is expected to surpass the first-generation technology across key performance metrics, with a list price set at $425,000 to balance premium value and accessibility [11][78] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, prioritizing long-term platform adoption over short-term revenue maximization [24][26] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][26] Other Important Information - The company has a strong balance sheet with $215.8 million in cash and investments, allowing it to support operations into the second quarter of 2028 [23][25] - Insider ownership remains significant, with no management team members selling shares outside of plan-mandated selling for tax withholdings [27] Q&A Session Summary Question: What are the trends in consumables within the installed base? - Management noted consistent purchasing rates from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [29] Question: Should we expect very few placements in 2026 with most revenue from consumables? - Management confirmed that revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [31][32] Question: How should we think about the launch curve for Proteus? - Management indicated that existing Platinum users will likely transition to Proteus, while new customers may adopt it based on its capabilities [34][35] Question: Does the $98 million in guidance for operating expenses include stock compensation? - Management clarified that the adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [41] Question: Is there confidence in the price point for Proteus based on customer feedback? - Management stated that the price point was released to assist customers in capital planning, with no secured orders yet but positive feedback from discussions [45][47] Question: What applications are expected to provide a tailwind for Proteus? - Management highlighted the potential for Proteus in complex biological samples and post-translational modifications, which are key areas of focus [64][66] Question: Will there be an increase in the field sales force for Proteus? - Management confirmed that the total spend for 2026 includes augmenting the commercial team to be launch-ready for Proteus [67][68]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, with adjusted operating expenses at $18.3 million compared to $26.7 million in the prior year [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [29] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][10] - The NIH funding environment has shown some improvement, which may positively impact customer capital expenditures [49] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as its corporate priorities for 2025 [4][18] - The focus for 2026 is on developing the market for Proteus, with a deliberate strategy to prioritize long-term platform adoption over short-term revenue maximization [24][26] Management's Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, with expectations of limited capital sales and a focus on consumable revenue [5][24] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][26] Other Important Information - The list price for Proteus has been set at $425,000, aimed at balancing premium value with accessibility for potential customers [11][78] - The company has a strong balance sheet with $215.8 million in cash and investments, allowing for strategic execution into 2028 [23][25] Q&A Session Summary Question: What are the trends in consumables within the installed base? - Management noted a consistent purchase rate from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [29] Question: Should we expect very few placements in 2026 with most revenue from consumables? - Management confirmed that revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [31][32] Question: How should we think about the launch curve for Proteus? - Management indicated that existing Platinum users will likely transition to Proteus, while new customers may adopt at varying rates based on application availability and financial incentives [34][35] Question: Does the $98 million in guidance for operating expenses include stock compensation? - Management clarified that the adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [41] Question: Is there confidence in the price point for Proteus based on customer feedback? - Management stated that the price point was released to assist customers in capital planning, with no secured orders yet but positive feedback from discussions with potential customers [45][46] Question: Will Proteus be available through leasing or rental options? - Currently, the company plans to launch Proteus with direct capital sales only, with potential for other acquisition models to be evaluated based on market feedback [81]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, while full-year operating expenses were $117.3 million, compared to $110.2 million in 2024 [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [31] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][12] - The NIH funding environment is showing signs of improvement, which may positively impact customer capital spending [50] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as it prepares for the Proteus launch [4][18] - The Proteus system is expected to surpass the first-generation technology across key performance metrics, with a list price set at $425,000 to balance premium value and accessibility [12][80] Management Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, prioritizing long-term platform adoption over short-term revenue maximization [25][27] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][28] Other Important Information - The company has a strong balance sheet with $215.8 million in cash and investments, allowing it to support operations into the second quarter of 2028 [24][26] - Insider ownership remains significant, with no management team members selling shares outside of plan-mandated selling for tax withholdings [28] Q&A Session Summary Question: What are the trends in consumables within the installed base? - The company is seeing consistent purchasing rates from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [30][31] Question: Should we expect very few placements in 2026, with most revenue from consumables? - Yes, the revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [33][34] Question: Can you discuss the launch curve for Proteus? - The launch will likely follow an S-curve, with existing Platinum users transitioning to Proteus and new customers being engaged [36][39] Question: Does the $98 million in guidance for operating expenses include stock compensation? - The adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [42] Question: Is the price point for Proteus based on secured pre-orders? - No secured orders are in place; the price is released to assist customers in their capital planning [46][47] Question: Will there be a rental program for Proteus? - Currently, only direct capital sales have been announced, with potential for other acquisition models to be evaluated based on market feedback [83]

Core Insights - Quantum-Si (QSI) reported a significant revenue shortfall in Q2 2025, with GAAP sales of $0.59 million, missing analyst estimates of $1.11 million by nearly 46.7% [1][5] - The company maintained a gross margin of 59%, an improvement from 57% in the prior year, despite ongoing struggles with commercial traction, particularly in U.S. academic markets [2][7] - QSI's accumulated deficit increased to $644.7 million as of June 30, 2025, highlighting the need for a clear path to sales growth to address sustained losses [8][15] Financial Performance - Q2 2025 GAAP revenue was $0.59 million, down 29.8% sequentially from Q1 2025 and a 5.0% decline year-over-year from Q2 2024 [2][5] - Earnings per share (EPS) for Q2 2025 was $(0.16), consistent with the same quarter last year [2] - Adjusted total operating expenses were $23.8 million, a decrease of 2.5% from the previous year, while adjusted EBITDA was negative $22.2 million [2][8] Business Overview - Quantum-Si focuses on next-generation protein sequencing technology aimed at making protein analysis more scalable and cost-effective [3] - The company is working on the launch of its Proteus platform, expected to enhance output and automation, with a prototype scheduled for late 2025 and commercial launch in the second half of 2026 [4][9] - The firm has expanded its international distributor network to 23 partners, indicating a strategic shift towards non-U.S. and non-academic customer segments [6] Product Development and Innovation - The company continues to invest in innovation, with upcoming product launches including the Version 4 Sequencing Kit in Q3 2025 and a new Version 3 Library Preparation Kit expected later in the year [9][10] - QSI's intellectual property portfolio includes nearly 400 issued patents and close to 600 pending, providing a competitive advantage [12] Market Strategy and Outlook - Management has increased academic outreach through webinars and user groups to drive demand and adoption of its technology [11] - The company raised an additional $50 million through a direct stock offering, which should fund operations into the second quarter of 2028, providing some financial breathing room [13] - Key issues for investors include the pace of commercial adoption outside U.S. academic markets and the need for recurring consumable sales to signal instrument utilization [15]